Celebrating Success: Major Achievement in COMBACTE-CARE

Read more
combacte-care News Item

New ESCMID President: Jesús Rodríguez Baño

During ECCMID 2018, COMBACTE-CARE’s management board member Prof. Dr. Jesús Rodríguez Baño effectively became ESCMID President for a two-year term.

Dr. Rodriguez-Baño is Head of Infectious Diseases Division at Hospital Universitario Virgen Macarena, and Professor of Medicine at Universidad de Sevilla. He is also the scientific coordinator of the Spanish Network for Research in Infectious Diseases (REIPI).

“I feel very honored to have the opportunity to be ESCMID President.  It is probably one of the most important achievements I could dream of. It comes with a great deal of responsibility and work for all the activities that take place, while living up to the high expectations. During my term as President Elect I received a good training about the Presidency term, but the ESCMID management is a team work in which all the Executive Committee and many more members are involved.

My priorities as president will be to consolidate previous ESCMID activities. There are a lot of ongoing things such as observership programs, membership programs, educational programs, EUCAST and EUCIC activities, etc.”

With ECCMID 2018 coming to end, preparations for the next congress that will take place in Amsterdam, the Netherlands will be soon commencing.

JRB: “We have set up a call for proposals for activities and sessions in the next congress, which will be submitted to us in the next few weeks. The first meeting with the Program Committee regarding the program for ECCMID 2019 in Amsterdam will take place in June. The Program Committee members have already been selected and informed about the first meeting. ECCMID Program Director Prof. Winfried Kern is also Program Committee Director for ECCMID 2019.”

 

Jesús Rodríguez Baño talks about COMBACTE’s private-public partnership in an interview for the 2nd Edition of the COMBACTE Magazine. Read about his insights on the collaboration with the industry, and the advantages of working together on page 16.

20/04/2024

EMA recommends Marketing Authorization for ATM-AVI

23/03/2024

Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

COMBACTE is proud to announce a significant milestone achieved in COMBACTE-CARE. The European Medicines Agency (EMA) has recommended granting a market...

28/09/2023

REVISIT: A Novel Tool to Treat Highly-Resistant Pathogens?